---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-176718"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2022-06-21T23:59:59+00:00"
generated_at: "2026-06-25T00:25:56.804461+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics amends bylaws for universal proxy rules and exclusive federal forum for Securities Act claims

## Summary
- Board amended bylaws on June 14, 2022 to incorporate universal proxy rules for director nominations.
- Forum selection provision changed to make U.S. federal district courts exclusive for Securities Act claims.
- Amended and restated bylaws filed as Exhibit 3.1 to the 8-K.

## SEC filing metadata
- accession: 0001193125-22-176718
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2022-06-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312522176718/0001193125-22-176718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312522176718/d277212d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-176718
- JSON: https://secwatch.observer/filing/0001193125-22-176718.json
- Plain text: https://secwatch.observer/filing/0001193125-22-176718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.